B - Summary of pharmacokinetic (PK) and pharmacodynamic (PD)
interactions of interest concerning non-immunosuppressive anticancer
drugs and potential COVID-19 treatments.
No interaction driven by other cytochromes were found. Red arrows are
for interactions relying on clinically significant data. Orange arrows
are for interactions relying on in vitro data for pharmacokinetic
interactions. Cytochromes involved in the drug interaction were
specified. Substrates for which induction but not inhibition could lead
to significant interaction are between brackets. When the interaction
modifies the pharmacokinetics of the anticancer drug, the arrow was on
the bottom-left. Antiviral exposition prediction is on the top-right.
Red boxes are for anticancer drugs with known Torsade-de-Pointes risk
and high risk of renal and liver toxicities. Orange boxes are for
anticancer drugs prolonging QT without known Torsade-de-Pointes risk and
moderate risk for renal and liver toxicities.
Data from FDA labels [4] were retrieved for drug metabolism, QT
prolongation, and nephrotoxicity. Livertox database was used for
hepatotoxicity[5].